Carmell CORP 8-K filings

Kathryn Gregory has resigned from the Board of Directors of Longevity Health Holdings, Inc., effective June 1, 2026.

Longevity Health Holdings, Inc. announced a strategic private placement and the appointment of Janakiram Ajjarapu as its new Chairman and Chief Executive Officer, signaling a shift towards an acquisition-focused growth strategy.

Longevity Health Holdings, Inc. announced the termination of its merger agreement with True Health Inc. after the transaction was not consummated by the November 30, 2025 deadline.

Longevity Health Holdings, Inc. amended its merger agreement with True Health Inc. to adjust the calculation of merger and earnout shares based on a market price floor.

Longevity Health Holdings, Inc. has been delisted from the Nasdaq Capital Market and its securities have commenced trading on the OTC marketplace due to a listing rule deficiency.

Longevity Health Holdings, Inc. has entered into a definitive all-stock merger agreement with True Health Inc. (THPlasma), a rapidly growing plasma collection company, while simultaneously terminating its previous merger agreement with 20/20 BioLabs, Inc. without penalty.

Longevity Health Holdings, Inc. has amended its merger agreement with 20/20 Biolabs, Inc. to extend the due diligence contingency deadline to July 8, 2025, indicating ongoing progress but also the potential for termination if conditions are not met.

Longevity Health Holdings, Inc. announced the successful sale of 479,621 shares of common stock through an at-the-market offering, raising approximately $1.96 million and extending its cash runway into Q1 FY26.

Longevity Health Holdings secures Nasdaq extension to meet initial listing requirements post-merger with 20/20 Biolabs by September 2, 2025.

Longevity Health Holdings reports preliminary Q1 2025 sales increase, finalizes merger agreement with 20/20 BioLabs, and plans new product launches and additional financing.

Longevity Health Holdings implemented a 1-for-30 reverse stock split to increase its stock price and maintain Nasdaq compliance.

Longevity Health Holdings announces a merger agreement with 20/20 BioLabs to expand into diagnostics and address chronic disease management.

Longevity Health Holdings has received a notification from Nasdaq regarding its failure to regain compliance with the minimum bid price requirement, potentially leading to delisting.

Longevity Health Holdings finalizes the acquisition of PMGC Holdings' skincare business, aiming to expand its market presence.

Longevity Health Holdings' stockholders approved the issuance of shares upon warrant exercise and a reverse stock split at a special meeting on March 24, 2025.

Carmell Corporation changes its name to Longevity Health Holdings, Inc. to better reflect its business focus and growth strategy, projecting $3 to $4 million in FY25 revenues.

Carmell Corporation received notice from Nasdaq that it failed to regain compliance with the minimum Market Value of Listed Securities (MVLS) requirement and faces potential delisting.

Carmell Corporation has announced the departure of CEO Kendra Bracken-Ferguson, with Executive Chairman Rajiv Shukla stepping in as her replacement, effective January 24, 2025.

Carmell Corporation has completed the acquisition of Elevai Skincare's business, expanding its product portfolio and commercial reach.

Carmell Corporation has entered into an agreement to acquire the assets of Elevai Skincare, a move aimed at expanding its presence in the bio-aesthetics market.

Carmell Corporation has announced a private placement of common stock and warrants, expected to generate $1.85 million in gross proceeds, to support its commercial build-out.

Carmell Corporation released an investor presentation detailing its bio-aesthetics technology, operational advancements, and commercialization strategy, emphasizing its science-backed approach to skincare.

Carmell Corporation received a notice from Nasdaq for failing to maintain a minimum share price of $1, putting its listing status at risk.

Carmell Corporation received a notice from Nasdaq stating that its market value of listed securities fell below the required $35 million, putting it at risk of delisting.

Carmell Corporation has appointed Kendra Bracken-Ferguson as its new CEO, effective July 30, 2024, as the company focuses on expanding its presence in the beauty and wellness industry.

Carmell Corporation held its 2024 Annual Meeting of Stockholders on July 12, 2024, electing Richard Upton as a Class I director and ratifying Adeptus Partners, LLC as its independent auditor.

Carmell Corporation has successfully raised approximately $3 million through a private placement of common stock to new and existing investors, including its CEO.

Carmell Corporation has completed the sale of its subsidiary Axolotl Biologix, allowing the company to concentrate on its skincare product launch.

Carmell Corporation has divested its subsidiary Axolotl Biologix back to its original owners, refocusing on its bio-aesthetics business and skincare product launch.

Carmell Corporation, a bio-aesthetics company, has announced the addition of Dr. Bradley Calobrace, a renowned plastic surgeon, to its Scientific Advisory Board.